What Medications Work Like Ozempic? A Guide to GLP-1 Drugs for Weight Loss

Ozempic has become the shorthand for an entire revolution in metabolic medicine — but it is far from the only player on the field. Research published in the Journal of the ASEAN Federation of Endocrine Societies found that subcutaneous semaglutide — the active ingredient in Ozempic and Wegovy — produced an average weight reduction of nearly 12% from baseline in people with obesity who did not have diabetes. Those are the kinds of numbers that have physicians, patients, and pharmaceutical companies paying very close attention. But semaglutide is not alone. A growing class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) works through overlapping mechanisms, and understanding the differences between them can help you and your doctor make a far more informed decision about what belongs in your protocol.

GLP-1 is a hormone your gut naturally releases after eating. It signals the pancreas to secrete insulin, tells the brain you are full, and slows gastric emptying so nutrients are absorbed more gradually. Medications that mimic or extend this signal — GLP-1 receptor agonists — have been in clinical use for type 2 diabetes for years, but their weight loss potential has only recently been fully exploited through higher doses and longer-acting formulations. Ozempic (semaglutide 0.5–2 mg, weekly injection) was approved for diabetes. Wegovy (semaglutide 2.4 mg, weekly injection) is the same molecule at a higher dose, approved specifically for chronic weight management. Understanding that distinction matters because the dose dramatically shapes the outcome.

The GLP-1 Drugs That Compete With — and Compare To — Semaglutide

Liraglutide, sold as Victoza for diabetes and Saxenda for weight loss, was the first GLP-1 RA approved specifically for obesity management. It requires a daily injection rather than weekly, and that difference in convenience translates directly into real-world outcomes. The STEP 8 randomized clinical trial, published in JAMA, ran a head-to-head comparison of once-weekly semaglutide 2.4 mg against once-daily liraglutide 3.0 mg over 68 weeks. Semaglutide produced a mean weight loss of 15.8% compared to 6.4% with liraglutide — a difference of more than 9 percentage points. Nearly 71% of semaglutide users lost at least 10% of their body weight, versus just 26% on liraglutide. Discontinuation rates told a similar story: 27.6% of liraglutide users stopped treatment compared to 13.5% on semaglutide. Liraglutide still works — it is a legitimate, FDA-approved weight loss medication — but by most measurable outcomes, semaglutide has outpaced it significantly.

Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, is the newest approved agent and arguably the most potent currently available. It is technically a dual agonist, activating both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. That dual mechanism appears to deliver additive metabolic benefits beyond what GLP-1 activation alone achieves. A 2025 narrative review in Diabetes, Obesity and Metabolism examining real-world data on approved GLP-1-based weight loss therapies confirmed that semaglutide and tirzepatide produce the most substantial outcomes among current options, with real-world results trending closely to trial data in highly adherent patients. The same review noted that discontinuation rates in clinical practice run between 20% and 50% within the first year — a sobering reminder that the medication is only as effective as the commitment to stay on it.

Exenatide (Byetta, Bydureon) is an older GLP-1 RA derived from Gila monster saliva — a genuinely strange piece of pharmacological history — and while it remains in use for diabetes, it has largely been eclipsed for weight management purposes by newer, more potent options. Dulaglutide (Trulicity) is another weekly GLP-1 RA approved for type 2 diabetes that produces modest weight loss as a secondary benefit, though it was never developed specifically as an obesity drug. These older agents occupy space in diabetes management but rarely lead the conversation around weight optimization today.

What the Next Generation of GLP-1 Drugs Looks Like

The pipeline beyond what is currently approved is remarkably active. A comprehensive 2025 systematic review in Pharmacological Reviews catalogued 53 phase 2 and phase 3 clinical trials across 36 emerging anti-obesity drugs, many of them incretin-based. Oral semaglutide at 50 mg — a pill rather than an injection — has already completed a phase 3 trial, a development that could dramatically change accessibility and adherence for patients who are needle-averse. Orforglipron is a once-daily oral GLP-1 RA in phase 3 development with early data showing meaningful weight loss without the injection requirement. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, with phase 2 data showing weight loss reaching 24% — numbers that approach what bariatric surgery has historically produced. CagriSema, a combination of semaglutide and cagrilintide (an amylin analogue), is in phase 3 trials and leverages two entirely separate satiety pathways. The field is evolving fast enough that any assessment made today may look conservative within 18 months.

It is worth stating clearly that none of these medications are magic. The STEP 3 trial published in JAMA — which paired semaglutide with intensive behavioral therapy and an initial low-calorie diet — produced a 16% mean weight loss from baseline. That is among the best outcomes in any trial. But notice what surrounds the drug in that protocol: 30 counseling visits, a structured diet phase, and consistent behavioral support. The men getting the best results from GLP-1 medications are using them as one lever among many, not as a substitute for training hard, eating with intention, and sleeping enough. Resistance training while on a GLP-1 is not optional — it is how you preserve the muscle mass that would otherwise be lost during aggressive caloric restriction. That principle applies whether you are on semaglutide, tirzepatide, or eating in a deficit through willpower alone.

The Takeaway

Ozempic is semaglutide, and semaglutide is currently the most widely prescribed GLP-1 receptor agonist for weight management — but it sits within a broader and rapidly expanding class of drugs. Liraglutide works but falls well short of semaglutide’s efficacy in direct comparison. Tirzepatide matches or exceeds semaglutide in most outcome measures and is poised to become the new benchmark. Oral options and triple-receptor agonists are coming down the pipeline faster than most people realize. If you are evaluating whether a GLP-1 medication belongs in your health plan, the conversation with your physician should not just be about whether to use one — it should be about which one, at what dose, combined with what lifestyle infrastructure, for how long. The drug is the tool. What you build with it depends on everything else you bring to the table.